-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Nuocheng Jianhua announced today that the company's Bruton's tyrosine kinase (BTK) inhibitor abutinib for the treatment of multiple sclerosis (MS) has passed the China National Medical Products Administration (NMPA) clinical research new drug (IND) review and approved to conduct Phase II clinical studies in China.
This is an international multi-center clinical phase II study evaluating the use of abutinib in patients with multiple sclerosis.
MS is an autoimmune central nervous system disease.
According to data released by the Multiple Sclerosis International Federation (MSIF), more than 2.
[1] [2]
According to the Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China in 2020, more than 43% of patients are unable to take care of themselves and need care by others.
[3]
[1] Data source: Multiple Sclerosis International Federation (MSIF) official website
[1] Data source: Multiple Sclerosis International Federation (MSIF) official websitestyle="text-indent:2em;margin-top:20px;"> [2] Data source: Frost & Sullivan analysis[3] Data source: China Rare Disease Alliance: "2020 Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China"
[3] Data source: China Rare Disease Alliance: "2020 Comprehensive Social Survey Report on Patients with Multiple Sclerosis in China"